HK1063471A1 - Pyrrolidine derivatives as factor xa inhibitors. - Google Patents

Pyrrolidine derivatives as factor xa inhibitors.

Info

Publication number
HK1063471A1
HK1063471A1 HK04106291A HK04106291A HK1063471A1 HK 1063471 A1 HK1063471 A1 HK 1063471A1 HK 04106291 A HK04106291 A HK 04106291A HK 04106291 A HK04106291 A HK 04106291A HK 1063471 A1 HK1063471 A1 HK 1063471A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
factor
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
HK04106291A
Other languages
English (en)
Inventor
Chuen Chan
Julie Nicole Hamblin
Henry Anderson Kelly
Kigel Paul King
Andrew Mcmurtrie Mason
Vipulkumar Kantibhai Patel
Stefan Senger
Gita Punjabhai Shah
Nigel Stephen Watson
Helen Elisabeth Weston
Caroline Whitworth
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1063471A1 publication Critical patent/HK1063471A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK04106291A 2001-06-08 2004-08-23 Pyrrolidine derivatives as factor xa inhibitors. HK1063471A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
HK1063471A1 true HK1063471A1 (en) 2004-12-31

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106291A HK1063471A1 (en) 2001-06-08 2004-08-23 Pyrrolidine derivatives as factor xa inhibitors.

Country Status (29)

Country Link
US (4) US7186717B2 (ja)
EP (1) EP1395553B1 (ja)
JP (1) JP4242274B2 (ja)
KR (1) KR100877245B1 (ja)
CN (1) CN1256324C (ja)
AR (1) AR036086A1 (ja)
AT (1) ATE289294T1 (ja)
AU (1) AU2002311451B2 (ja)
BR (1) BR0210207A (ja)
CA (1) CA2449629A1 (ja)
CO (1) CO5540285A2 (ja)
CZ (1) CZ20033325A3 (ja)
DE (1) DE60203006T2 (ja)
DK (1) DK1395553T3 (ja)
ES (1) ES2235050T3 (ja)
GB (1) GB0114005D0 (ja)
HK (1) HK1063471A1 (ja)
HU (1) HUP0400156A3 (ja)
IL (1) IL159195A0 (ja)
MX (1) MXPA03011384A (ja)
MY (1) MY136859A (ja)
NO (1) NO326689B1 (ja)
NZ (1) NZ530004A (ja)
PL (1) PL368082A1 (ja)
PT (1) PT1395553E (ja)
SI (1) SI1395553T1 (ja)
TW (1) TWI298719B (ja)
WO (1) WO2002100830A1 (ja)
ZA (1) ZA200309367B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
DK1637141T3 (da) 2004-09-21 2012-02-27 Trobio Ab Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen
AU2005299693B2 (en) * 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
CA2621059C (en) * 2005-09-22 2013-08-13 Trobio Ab Stabilized protease composition
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
MX360896B (es) * 2013-04-26 2018-11-21 Sanofi Sa Sal tartrato de la [ (s)-2-[metil-3-(2-oxo-pirrolidin-1-il)-bencen osulfonilamino]-3-(4-metil-piperazin-1-il)-3-oxo-propil) amida de acido 5-cloro-tiofeno-2-carboxilico.
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
CA2268281A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU726637B2 (en) 1996-12-13 2000-11-16 Aventis Pharmaceuticals Inc. Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
BR9815377A (pt) * 1997-09-30 2001-01-16 Daiichi Pharmaceutical Co Ltda Derivados de sulfonil
ATE346050T1 (de) 1998-01-27 2006-12-15 Aventis Pharma Inc Substituierte oxoazaheterocyclyl faktor xa hemmer
CA2329300A1 (en) 1998-04-22 1999-10-28 Showa Denko K.K. Particulate metal oxide with evenly fluorinated surface, process for producing the same, and use
CA2358939A1 (en) 1998-12-31 2000-07-13 Joseph P. Burkhart 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
JP2002536437A (ja) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー ＦＸａのラクタム抑制剤および方法
AU3192500A (en) 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
WO2000069465A1 (fr) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
MXPA02000888A (es) 1999-07-28 2002-07-30 Aventis Pharm Prod Inc Compuestos de oxoazaheterociclilos substituidos.
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ZA200309367B (en) 2004-08-02
PL368082A1 (en) 2005-03-21
PT1395553E (pt) 2005-06-30
NO20035440D0 (no) 2003-12-05
CO5540285A2 (es) 2005-07-29
KR100877245B1 (ko) 2009-01-07
TWI298719B (en) 2008-07-11
US20050107379A1 (en) 2005-05-19
KR20040004706A (ko) 2004-01-13
AR036086A1 (es) 2004-08-11
MXPA03011384A (es) 2004-04-05
CN1256324C (zh) 2006-05-17
CZ20033325A3 (cs) 2004-08-18
ATE289294T1 (de) 2005-03-15
JP2004537530A (ja) 2004-12-16
BR0210207A (pt) 2004-08-03
US7326785B2 (en) 2008-02-05
ES2235050T3 (es) 2005-07-01
CA2449629A1 (en) 2002-12-19
DE60203006T2 (de) 2006-03-30
IL159195A0 (en) 2004-06-01
JP4242274B2 (ja) 2009-03-25
HUP0400156A3 (en) 2008-10-28
WO2002100830A1 (en) 2002-12-19
GB0114005D0 (en) 2001-08-01
AU2002311451B2 (en) 2006-03-02
NZ530004A (en) 2005-08-26
US20070142374A1 (en) 2007-06-21
US20070155745A1 (en) 2007-07-05
EP1395553A1 (en) 2004-03-10
CN1538955A (zh) 2004-10-20
NO326689B1 (no) 2009-01-26
DE60203006D1 (de) 2005-03-24
US7186717B2 (en) 2007-03-06
SI1395553T1 (en) 2005-06-30
MY136859A (en) 2008-11-28
US7429587B2 (en) 2008-09-30
HUP0400156A2 (hu) 2004-07-28
DK1395553T3 (da) 2005-06-06
EP1395553B1 (en) 2005-02-16
US7517879B2 (en) 2009-04-14
US20070142375A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
AU2002350217A8 (en) Glycinamides as factor xa inhibitors
HK1070352A1 (en) Indole-2-carboxamides as factor xa inhibitors
AU2001273040A1 (en) Factor xa inhibitors
IL169323A0 (en) Pyrazole-derivatives as factor xa inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
ZA200306490B (en) Inhibitors of factor Xa.
HK1061973A1 (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AP2005003198A0 (en) Spiroindolinepiperidine derivatives.
ZA200500170B (en) Indole-3-sulphur derivatives.
HK1068608A1 (en) 3-Substituted-4-pyrimidone derivatives
HK1063471A1 (en) Pyrrolidine derivatives as factor xa inhibitors.
AU2003235913A1 (en) Cyanopyrrolidine derivatives
SI1268419T1 (sl) Pirolidinski derivati, uporabni kot bax inhibitorji
IL162454A0 (en) Pyrrolidine-2-ones as factor xa inhibitors
HK1068607A1 (en) Phenylalkyloxy-phenyl derivatives
EP1379245A4 (en) 1, 4, 5, 6-TETRAHYDROPYRAZOLO- 3, 4-C-PYRIDINE-7-ONE AS FACTOR XA HEMMER
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
AU2003257637A1 (en) Proline derivatives
AU2003296393A1 (en) Factor xa inhibitors
MXPA03004331A (es) Derivados novedosos de carbapenem.
AU2002348501A1 (en) Factor xa inhibitor
AU2002325882A1 (en) Phenyl derivatives as factor Xa inhibitors
EP1364954A4 (en) Dicarba closo DODECARBORANDERIVATE
AU2002256270A1 (en) 1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-ones as factor xa inhibitors
GB0104583D0 (en) Piperidine derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110606